Literature DB >> 25400776

Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population.

Shu Liu1, Bingfei Zhang1, Yanru Zhao1, Pu Chen1, Meiju Ji1, Peng Hou1, Bingyin Shi1.   

Abstract

BACKGROUND: The new finding of the heterogeneous distribution of BRAF(V600E) mutation in primary papillary thyroid carcinoma suggested the percentage of BRAF(V600E) alleles should be taken into consideration when evaluating its association with clinicopathological features of papillary thyroid carcinoma. The aim of this study was to detect both the presence and the percentage of BRAF(V600E) alleles in fine-needle aspiration biopsy samples and to assess its association with clinicopathological characteristics of papillary thyroid carcinoma in a Chinese population.
MATERIALS AND METHODS: Fine needle aspiration samples were collected in a total of 182 patients (132 conventional papillary thyroid carcinomas and 50 goiters). The associations of the presence and percentage of BRAF(V600E) alleles genotyped by pyrosequencing with clinicopathological characteristics were evaluated in papillary thyroid carcinomas.
RESULTS: 80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.3% of the total BRAF alleles. The presence of BRAF(V600E) mutation was significantly associated with extrathyroidal invasion. There was no significant difference between the presence of BRAF(V600E) mutation and other clinicopathological features. It was not found that the significant relationship between percentage of BRAF(V600E) alleles and clinicopathological characteristics.
CONCLUSION: We concluded that the presence of BRAF(V600E) could be preoperatively predictive of extrathyroidal invasion in a Chinese population.

Entities:  

Keywords:  Papillary thyroid carcinoma (PTC); percentage of BRAFV600E alleles; preoperative risk stratification; pyrosequencing

Mesh:

Substances:

Year:  2014        PMID: 25400776      PMCID: PMC4230084     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

2.  BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.

Authors:  Valentina Sancisi; Davide Nicoli; Moira Ragazzi; Simonetta Piana; Alessia Ciarrocchi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-27       Impact factor: 5.958

3.  Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.

Authors:  Shu Liu; Aibo Gao; Bingfei Zhang; Zhaoxia Zhang; Yanru Zhao; Pu Chen; Meiju Ji; Peng Hou; Bingyin Shi
Journal:  Exp Mol Pathol       Date:  2014-08-08       Impact factor: 3.362

Review 4.  BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.

Authors:  Ralph P Tufano; Gilberto V Teixeira; Justin Bishop; Kathryn A Carson; Mingzhao Xing
Journal:  Medicine (Baltimore)       Date:  2012-09       Impact factor: 1.889

5.  A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up.

Authors:  Raymon H Grogan; Sharone P Kaplan; Hongyuan Cao; Roy E Weiss; Leslie J Degroot; Cassie A Simon; Omran M A Embia; Peter Angelos; Edwin L Kaplan; Rebecca B Schechter
Journal:  Surgery       Date:  2013-09-26       Impact factor: 3.982

6.  Fine-needle aspiration biopsy in the management of thyroid nodules in children and adolescents.

Authors:  A Al-Shaikh; B Ngan; A Daneman; D Daneman
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

7.  Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.

Authors:  Jae Yun Lim; Soon Won Hong; Yong Sang Lee; Bup-Woo Kim; Cheong Soo Park; Hang-Seok Chang; Jae Yong Cho
Journal:  Thyroid       Date:  2013-09-27       Impact factor: 6.568

8.  BRAF V600E mutation and papillary thyroid cancer--in reply.

Authors:  Mingzhao Xing
Journal:  JAMA       Date:  2013-08-07       Impact factor: 56.272

9.  BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.

Authors:  Efisio Puxeddu; Sonia Moretti; Rossella Elisei; Cristina Romei; Raffaela Pascucci; Marco Martinelli; Cecilia Marino; Nicola Avenia; Esther Diana Rossi; Guido Fadda; Antonio Cavaliere; Rodolfo Ribacchi; Alberto Falorni; Alfredo Pontecorvi; Furio Pacini; Aldo Pinchera; Fausto Santeusanio
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Authors:  Xiulong Xu; Roderick M Quiros; Paolo Gattuso; Kenneth B Ain; Richard A Prinz
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  11 in total

1.  Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.

Authors:  Junliang Lu; Jie Gao; Jing Zhang; Jian Sun; Huanwen Wu; Xiaohua Shi; Lianghong Teng; Zhiyong Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 2.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

Review 3.  Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.

Authors:  Young Shin Song; Jung Ah Lim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2015-09

4.  BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.

Authors:  Eleonora Monti; Michela Bovero; Lorenzo Mortara; Giorgia Pera; Simonetta Zupo; Elena Gugiatti; Mariella Dono; Barbara Massa; Gian Luca Ansaldo; Giusti Massimo
Journal:  Int J Endocrinol       Date:  2015-11-26       Impact factor: 3.257

5.  Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.

Authors:  Chunping Liu; Tianwen Chen; Zeming Liu
Journal:  World J Surg Oncol       Date:  2016-09-06       Impact factor: 2.754

6.  Thyroid functional parameters and correlative autoantibodies as prognostic factors for differentiated thyroid cancers.

Authors:  Chao Li; Wenbin Yu; Jinchuan Fan; Guojun Li; Xiaofeng Tao; Yun Feng; Ronghao Sun
Journal:  Oncotarget       Date:  2016-08-02

7.  Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.

Authors:  Huan Yu; Meng Ma; Junya Yan; Longwen Xu; Jiayi Yu; Jie Dai; Tianxiao Xu; Huan Tang; Xiaowen Wu; Siming Li; Bin Lian; Lili Mao; Zhihong Chi; Chuanliang Cui; Jun Guo; Yan Kong
Journal:  J Transl Med       Date:  2017-12-04       Impact factor: 5.531

8.  Presurgical Screening of Fine Needle Aspirates from Thyroid Nodules for BRAF Mutations: A Prospective Single Center Experience.

Authors:  Ramamoorthy Hemalatha; Rekha Pai; Marie T Manipadam; Grace Rebekah; Anish J Cherian; Deepak T Abraham; Simon Rajaratnam; Nihal Thomas; Pooja Ramakant; Paul M Jacob
Journal:  Indian J Endocrinol Metab       Date:  2018 Nov-Dec

9.  Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis.

Authors:  Haoyu Ren; Yifan Shen; Daixing Hu; Wei He; Jing Zhou; Yijia Cao; Yu Mao; Yi Dou; Wei Xiong; Qi Xiao; Yuhong Zhang; Xinliang Su
Journal:  Cancer Manag Res       Date:  2018-05-03       Impact factor: 3.989

10.  Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.

Authors:  Min Li; Haitao Jia; Qiuqin Qian; Peng Wen; Chuan Chen; Yaqiong Hua; Kai Wang; Wenyong Zhang; Feng Shi
Journal:  Diagn Pathol       Date:  2020-05-11       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.